Drug intelligence / Profile preview

GBT009

Development stage: Phase 2
Lead developer: Garnet BioTherapeutics
Modality: Cell Therapies
Administration: Intradermal

Overview

GBT009 is an allogeneic cell therapy product composed of adult bone marrow-derived cells, developed by Garnet BioTherapeutics. It was designed to improve the appearance of surgical scars and enhance wound healing. The therapy is administered via intradermal injections along the edges of full-thickness surgical incisions. The mechanism of action involves the cells' ability to modulate the local wound environment, reducing inflammation and promoting regenerative processes over fibrotic scarring. Clinical development reached Phase 2 for the treatment of incisional wounds following breast reconstruction surgery, but the program appears to have stalled as the sponsor is no longer active.

Other names: human adult bone marrow-derived stromal cellshABM-SC

Beyond the preview

Go deeper on GBT009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GBT009.

Explore the full profile